access+affordability

The national pharmaceutical panel is scheduled to make its recommendation on Thursday, but the government will wait for a third panel, which has not said when it will reach its conclusion, before deciding whether to grant approval.

The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.

Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX programme and bolstering Beijing's push for a bigger role in inoculating the world.

That was up from 1.4 billion doses announced in March.

The potential cost-effectiveness estimates are significantly higher than what NICE considers to be an appropriate use of NHS resources.

Concerns have risen on potential side-effects of the Anglo-Swedish COVID-19 vaccine.

Western pharmaceutical companies, many of which have received government support to develop vaccines, strongly oppose the transfer of intellectual property to make them.

The solution is to ease restrictions on exporting shots and build more production capacity.

The new system in New Zealand will be up and running within two years.

California’s dentist and doctor lobbies say insurance companies are flush with cash after collecting premiums during the pandemic but paying fewer claims than usual—and should foot the bill.

The talks also are likely to focus on a waiver that is significantly narrower in scope and shorter in duration than the one initially proposed by India and South Africa last October.

The shifts in guidance on the Anglo-Swedish drugmaker's vector-based shot demonstrate just how hard it is for policy makers to weigh its benefits against risks in the form of very rare - yet occasionally fatal - cases of blood clotting.

The first batch of the Moderna vaccine had already arrived and an estimated 30 million doses of the AstraZeneca shot are being prepared by its local domestic partners.

Lab companies have been booking record profits by charging $100 per test.

European countries distanced themselves on Friday from a proposal backed by U.S. President Joe Biden to waive patent rights on coronavirus vaccines.